3
IXP, a lifesciences VC backed by JV Ventures, plans to raise Rs 200 crore through its maiden fund to invest in early-stage companies.
The fund aims to build a portfolio of business-to-business (B2B) companies ranging from pre-seed to series A stages. The IXP Lifesciences Catalyst Fund has a greenshoe option of Rs 100 crore with an investment horizon of 3-5 years targeting an internal rate of return (IRR) of 22 percentage and above.
“IXP was born out of a need we saw in the Indian start-up ecosystem. In fact, we conducted a pan-India survey to…
